Published in Curr Rheumatol Rep on January 01, 2013
Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol (2014) 0.88
The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int (2016) 0.79
Update on macrophages and innate immunity in scleroderma. Curr Opin Rheumatol (2015) 0.75
Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease. Auto Immun Highlights (2013) 0.75
Osteolysis Affecting the Jaws in Systemic Sclerosis: Clinical and Osseous Changes Based on a Case Presentation. Clin Med Insights Arthritis Musculoskelet Disord (2015) 0.75
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009) 11.63
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 10.34
Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature (2009) 9.71
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A (2010) 6.78
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol (1999) 6.19
IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med (2005) 5.13
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med (2008) 4.70
Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (1993) 3.67
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med (2008) 3.62
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 3.39
IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol (2008) 3.09
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med (2003) 2.71
Interleukin-4 and interleukin-13 signaling connections maps. Science (2003) 2.69
Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One (2008) 2.66
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol (1998) 2.57
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med (2003) 2.54
IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol (2007) 2.38
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest (2002) 2.22
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum (2007) 2.11
Role of IL-33 in inflammation and disease. J Inflamm (Lond) (2011) 2.06
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A (2012) 1.99
Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2002) 1.95
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol (1997) 1.95
Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol (2012) 1.91
Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol (2012) 1.85
IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2002) 1.81
Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol (2009) 1.79
Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) (2006) 1.77
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol (2011) 1.66
Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol (2010) 1.64
Target antigens determine graft-versus-host disease phenotype. J Immunol (2004) 1.57
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol (1999) 1.45
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A (2007) 1.39
HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum (2009) 1.36
Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol (2008) 1.35
Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum (2011) 1.31
Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) (2008) 1.31
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol (2010) 1.17
Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum (2010) 1.16
Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol (1983) 1.15
Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol (1998) 1.15
The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res (2006) 1.12
Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling. J Immunol (2006) 1.11
Biology of the scleroderma fibroblast. Curr Opin Rheumatol (1998) 1.10
Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med (2011) 1.10
Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am J Respir Crit Care Med (2004) 1.07
A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum (2004) 1.07
Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am (1996) 1.07
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis (2010) 1.05
IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep (2007) 1.04
Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol (2003) 1.04
Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol (2011) 1.03
Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol (2011) 1.03
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum (2009) 1.03
GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum (2011) 1.01
Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One (2009) 0.99
IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis (2012) 0.98
The genetics of systemic sclerosis: an update. Clin Exp Rheumatol (2011) 0.98
Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum (2010) 0.97
Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics (2006) 0.97
Animal model of systemic sclerosis. J Dermatol (2010) 0.97
Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) (2008) 0.95
dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis (2010) 0.92
Genetics of systemic sclerosis: an update. Curr Rheumatol Rep (2012) 0.90
A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther (2012) 0.90
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis (2009) 0.89
Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep (2010) 0.89
Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol (2004) 0.89
Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol (2011) 0.88
The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol (1999) 0.88
IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol (2006) 0.86
Animal models of scleroderma: fresh insights. Curr Opin Rheumatol (2010) 0.85
Endothelin and scleroderma lung disease. Rheumatology (Oxford) (2008) 0.81
Autoimmunity as a secondary phenomenon in scleroderma (and so-called human adjuvant disease). Med Hypotheses (1991) 0.79
Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis (2011) 0.77
Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol (2011) 0.76
NFATc1 balances quiescence and proliferation of skin stem cells. Cell (2008) 3.81
Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest (2012) 1.72
NFATc1 and NFATc2 repress spontaneous osteoarthritis. Proc Natl Acad Sci U S A (2013) 1.61
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol (2012) 1.32
Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One (2012) 1.16
Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev (2010) 1.06
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest (2011) 1.05
HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci U S A (2008) 1.02
Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum (2013) 1.00
SLC4A2-mediated Cl-/HCO3- exchange activity is essential for calpain-dependent regulation of the actin cytoskeleton in osteoclasts. Proc Natl Acad Sci U S A (2013) 0.90
Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A (2012) 0.90
The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone (2012) 0.87
Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol (2011) 0.76
Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis. Arthritis Res Ther (2014) 0.75